Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant
Substance P (SP) and its receptor neurokinin 1 (NK1R) are thought to be involved in the pathogenesis of chronic prurigo. Here, we assessed SP serum levels, cutaneous NK1R expression, and the effects of topical aprepitant, an NK1R antagonist, in patients with chronic prurigo. SP and NK1R were increas...
Saved in:
Main Authors: | Tatevik Ohanyan (Author), Nicole Schoepke (Author), Stefan Eirefelt (Author), Gert Hoey (Author), Witte Koopmann (Author), Tomasz Hawro (Author), Marcus Maurer (Author), Martin Metz (Author) |
---|---|
Format: | Book |
Published: |
Medical Journals Sweden,
2017-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review
by: Zaid Z. Almustafa, et al.
Published: (2019) -
Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)
by: Athanasios Tsianakas, et al.
Published: (2019) -
Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis
by: Louise Lönndahl, et al.
Published: (2017) -
The role of neurokinin-1 (substance P) antagonists in the prevention of postoperative nausea and vomiting
by: Dionne Okafor, et al.
Published: (2017) -
Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study
by: Tanja Todberg, et al.
Published: (2020)